Showing results (1281-1290 of 1,518) with videos related to
Sort By:
Pageof 152
JTO Clinical and Research Reports|April 13, 2026
Treatment Patterns, Outcome, and Quality of Life of Patients With Extensive-Stage SCLC Receiving Third-Line Therapy-Data From the German CRISP Registry (AIO-TRK-0315): A Brief ReportMaximilian Rost, Rieke Fischer, Martin Reck, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2019
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or GreaterMartin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.SLAS Technology|August 26, 2022
Integrated and automated high-throughput purification of libraries on microscaleCarol Ginsburg-Moraff, Jonathan Grob, Karl Chin, et al.Lung Cancer (Amsterdam, Netherlands)|October 23, 2025
Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adultsMichael Abele, Anton Karelin, Michaela Pogoda, et al.The Lancet. Oncology|February 21, 2012
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialLuis Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2013
PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerLuis G Paz-Ares, Filippo de Marinis, Mircea Dediu, et al.Dermatitis : Contact, Atopic, Occupational, Drug|March 2, 2018
Survey of Patch Test Business Models in the United States by the American Contact Dermatitis SocietyTian Hao Zhu, Raagini Suresh, Benjamin Farahnik, et al.Ticks and Tick-Borne Diseases|October 9, 2016
Multiple resistance to acaricides in field populations of Rhipicephalus microplus from Rio Grande do Sul state, Southern BrazilGuilherme Klafke, Anelise Webster, Bruno Dall Agnol, et al.The New England Journal of Medicine|October 11, 2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung CancerMartin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.Pageof 152